SIC
NVCR icon

Samalin Investment Counsel’s NovoCure NVCR Stock Holding History

Samalin Investment Counsel’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-411
Closed -$34K – 403
2019
Q4 		$34K Buy
+411
New +$33.2K 0.03% 326

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Samalin Investment Counsel's NVCR Position: Q1 2020 in Review

Samalin Investment Counsel sold out of NovoCure (NVCR) in Q1 2020, closing a stake of 411 shares — an estimated $34K sold.

Samalin Investment Counsel first reported a position in NVCR in Q4 2019 and held it in 1 quarter. The position peaked at $34K in Q4 2019. 271 funds tracked by Wall St. Rank hold NVCR as of Q1 2020.

  • Samalin Investment Counsel reported no remaining NovoCure position as of Q1 2020 after selling out during the quarter.
  • Samalin Investment Counsel sold 411 NovoCure shares in Q1 2020, an estimated $34K.
  • Samalin Investment Counsel first reported a position in NovoCure in Q4 2019 and held it in 1 quarter.
  • Samalin Investment Counsel's NovoCure position peaked at $34K in Q4 2019.
  • 271 funds tracked by Wall St. Rank held NovoCure as of Q1 2020.

Based on Samalin Investment Counsel's 13F filing for Q1 2020, filed 4 May 2020.